Clinical Trial Update: Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel followed by doxorubicin plus cyclophosphamide for node-positive or high-risk primary breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Adriamycin (doxorubicin)
• Cytoxan (cyclophosphamide)
• Taxotere (docetaxel)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED